Akero Therapeutics price target raised to $109 from $42 at UBS
UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong” ...
Fintel on MSN19h
B of A Securities Upgrades Akero Therapeutics (AKRO)
Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from ...
Akero raised to Buy at Bank of America after liver drug data
Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
STAT15h
RFK Jr.’s confirmation hearings, MASH drugs, and a controversial obesity ad
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
North American Morning Briefing: Investors in -2-
A midair collision between an American Airlines flight and an Army helicopter over the Potomac River killed all 67 people on the two aircraft, officials said Thursday, leaving investigators to piece ...
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
Navigating fragility of a highly valued and concentrated market
Josh Sheluk, portfolio manager at Verecan Capital Management Inc., shares his tips on how investors can navigate the fragility of a concentrated market.